About a half of HER2-negative breast cancer show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC samples. Patients with matched primary and relapse BC samples were included. 1299 patients were included.
Study Type
OBSERVATIONAL
Enrollment
1,299
no intervention was needed
Fudan University Shanghai Cancer Center
Shanghai, China
overall survival
The overall survival (OS) was defined as time from the date of initial diagnosis of recurrent/metastatic disease to the date of death from any cause
Time frame: up to 200 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.